Respiratory Distress Syndrome

Pipeline Programs↗

Active Trials↗

Companies Involved↗

Respiratory Distress Syndrome is an early-stage landscape with 0 programs across 1 company. The most active players are Chiesi Farmaceutici S.p.A..

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

77/100

Attrition Rate

16/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Chiesi Farmaceutici S.p.A.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

clinical trials

Completed10 · 53%

Withdrawn2 · 11%

Unknown status2 · 11%

Recruiting2 · 11%

Terminated1 · 5%

Not yet recruiting1 · 5%

Other1 · 5%

Clinical Trials

Trial Activity

19 trials

Pragmatic Evaluation of Respiratory Distress Syndrome Treatment in Africa

Recruiting·IIndiana University·Phase 4·NCT06554522·1,512 enrolled

Oxygen Delivery in CPAP and Its Relationship With Regional Lung Ventilation in Preterm Infants

Recruiting·UUniversity of Arkansas·Preclinical·NCT07674953·10 enrolled

Calfactant vs Poractant Alfa Using a Less Invasive Technique in Preterm Infants With Respiratory Distress Syndrome

Not yet recruiting·UUludag University·Phase 4·NCT07350018·234 enrolled

Surfactant Prophylaxis in LAte Preterm to Early Term Infants Using a Supraglottic Airway Device to Help Improve Outcomes

Enrolling by invitation·SSharp HealthCare·Preclinical·NCT07176117·422 enrolled

Delivery Room Management Trial of Premature Infants at High Risk of Respiratory Distress Syndrome

Completed·VVermont Oxford Network·Phase 3·NCT00244101·648 enrolled

Curosurf/Budesonide for Infants With Respiratory Distress Syndrome

Completed·—·N/A·NCT02013115·300 enrolled

Perfusion Index Variability in Respiratory Distress Syndrome

Completed·—·N/A·NCT01852461·92 enrolled

First In Human Study on Synthetic Surfactant CHF 5633 in Respiratory Distress Syndrome

Completed· Chiesi Farmaceutici S.p.A. logo

Chiesi Farmaceutici S.p.A.·Phase 1·NCT01651637·40 enrolled

Exosurf Neonatal and Survanta for Treatment of Respiratory Distress Syndrome

Completed·NNICHD Neonatal Research Network·Phase 2/3·NCT01203358·617 enrolled

Surfactant Replacement Guided by Early Lung Ultrasound Score in Preterm Newborns With Respiratory Distress Syndrome

Completed·—·N/A·NCT04775459·84 enrolled

Efficacy of Recombinant Human Clara Cell 10 Protein (rhCC10) Administered to Premature Neonates With Respiratory Distress Syndrome

Completed·TTufts Medical Center·Phase 2·NCT01941745·88 enrolled

Effects of Non-invasive Ventilation With Helium-oxygen Mixture in Premature Infants With Respiratory Distress Syndrome

Completed·PPoznan University of Medical Sciences·Phase 1/2·NCT04404816·23 enrolled

Human Surfactant Treatment of Respiratory Distress Syndrome Bicenter Trial

Completed·National Heart, Lung, and Blood Institute (NHLBI)·Phase 3·NCT00000570

Comparison of Curosurf and Infasurf in the Treatment of Preterm Infants With Respiratory Distress Syndrome

Completed·UUniversity of Missouri-Columbia·N/A·NCT02834624·30 enrolled

Surfactant Via Endotracheal Tube vs. Laryngeal Mask Airway (LMA) in Preterm Neonates With Respiratory Distress Syndrome

Terminated·—·Phase 4·NCT02164734·93 enrolled

Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)